HansBiomed Corporation (042520) - Total Liabilities
Based on the latest financial reports, HansBiomed Corporation (042520) has total liabilities worth ₩92.52 Billion KRW (≈ $62.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of HansBiomed Corporation to assess how effectively this company generates cash.
HansBiomed Corporation - Total Liabilities Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's total liabilities have evolved over time, based on quarterly financial data. Check 042520 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
HansBiomed Corporation Competitors by Total Liabilities
The table below lists competitors of HansBiomed Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Allspring Multi Sector Income Fund
NYSE MKT:ERC
|
USA | $126.61 Million |
|
ElringKlinger AG
F:ZIL2
|
Germany | €1.22 Billion |
|
Oponeo.pl SA
WAR:OPN
|
Poland | zł1.13 Billion |
|
In Win Development Inc
TW:6117
|
Taiwan | NT$3.22 Billion |
|
M3-Brigade Acquisition V Corp. Units
NASDAQ:MBAVU
|
USA | $20.70 Million |
|
Bhansali Engineering Polymers Limited
NSE:BEPL
|
India | Rs1.33 Billion |
|
Vitania Ltd
TA:VTNA
|
Israel | ILA2.07 Billion |
|
SOHO China Limited
F:45S
|
Germany | €31.13 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down HansBiomed Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 042520 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HansBiomed Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HansBiomed Corporation (2012–2025)
The table below shows the annual total liabilities of HansBiomed Corporation from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | ₩92.52 Billion ≈ $62.70 Million |
+69.47% |
| 2024-09-30 | ₩54.59 Billion ≈ $37.00 Million |
-24.62% |
| 2023-09-30 | ₩72.42 Billion ≈ $49.08 Million |
-15.84% |
| 2022-09-30 | ₩86.05 Billion ≈ $58.32 Million |
+1.25% |
| 2021-09-30 | ₩84.99 Billion ≈ $57.60 Million |
+18.92% |
| 2020-09-30 | ₩71.47 Billion ≈ $48.43 Million |
+42.87% |
| 2019-09-30 | ₩50.03 Billion ≈ $33.90 Million |
+88.82% |
| 2018-09-30 | ₩26.49 Billion ≈ $17.95 Million |
+0.12% |
| 2017-09-30 | ₩26.46 Billion ≈ $17.93 Million |
+47.83% |
| 2016-09-30 | ₩17.90 Billion ≈ $12.13 Million |
+99.90% |
| 2015-09-30 | ₩8.95 Billion ≈ $6.07 Million |
+80.81% |
| 2014-09-30 | ₩4.95 Billion ≈ $3.36 Million |
+22.19% |
| 2013-09-30 | ₩4.05 Billion ≈ $2.75 Million |
+34.55% |
| 2012-09-30 | ₩3.01 Billion ≈ $2.04 Million |
-- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more